Day One Biopharmaceuticals (Series A)
Funding Details
- Awarder
- Inbox
- Date Award
- May 21, 2020
- Vertical
- Biopharmaceuticals
- Funding URL
- View Funding Page
- Funding Amount:
- $60,000,000
Company Info
- Company Description
- Inspired by children with cancer, Day One Biopharmaceuticals creatively and intentionally develops promising new therapies that change the outcome for people of all ages living with cancer. Day One's first announced program is DAY101, an oral, once-a-week, type II pan-RAF inhibitor that is currently being evaluated in human clinical trials.
- Market
- Cancer treatment
- Location
- South San Francisco, California, USA
- Coinvestors
- Access Industries, Atlas Venture, Canaan Partners